Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2010

View Archived Issues

Sipuleucel-T is safe and well tolerated in CRPC and ADPC

CF-101 displays safety and potent anti-inflammatory activity

Eprosartan/bisoprolol shows efficacy in chronic heart failure and pulmonary hypertension

Lucinactant protects against IRI in experimental lung transplantation

Spermine identified as putative biomarker of stroke diagnosis and severity

Hedgehog signaling inhibitors claimed by Lilly for cancer therapy

Evotec presents new histamine H3 receptor antagonists

Biotie Therapies and Wyeth claim new PDE inhibitors

Boehringer Ingelheim identifies new collagenase 3 inhibitors

Abbott discloses highlights of first quarter 2010

Raptor licenses intellectual property related to treatment of Huntington's disease

FDA advisory committee reviews MedImmune's motavizumab BLA

FDA advisory committee review of lorcaserin set for September

Astellas announces second tender offer period for OSI share acquisition

FDA approves Roche Diagnostics' Elecsys anti-HCV assay

Aoxing and PPL to codevelop new pain and addiction therapies

Intercell partners with Inclinix for phase III trial of travelers' diarrhea vaccine

FDA grants orphan drug status to telatinib for gastric cancer

YM raises funds for phase II part of CYT-387 trial in myelofibrosis

CSL Behring's Berinert approved in Canada for HAE

Cephalon discontinues development of Nuvigil in schizophrenia

Phase II trial of Ocuseva in retinitis pigmentosa completed

Nabriva begins phase II BC-3781 trial in skin and skin structure infections

Tioga begins phase III asimadoline trial in irritable bowel syndrome

Phase I data presented on HuM195/rGel in advanced myeloid malignancies

CT-322 is active in phase II trial in recurrent glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...